These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12702887)

  • 21. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin.
    Fuchs PC; Barry AL; Brown SD
    J Chemother; 1997 Dec; 9(6):391-3. PubMed ID: 9491837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
    Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
    J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
    Bonfiglio G
    Chemotherapy; 2001; 47(4):239-42. PubMed ID: 11399859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
    Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
    Hosgor-Limoncu M; Ermertcan S; Tasli H; Yurtman AN
    West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.
    Callegan MC; Booth MC; Gilmore MS
    Cornea; 2000 Jul; 19(4):539-45. PubMed ID: 10928774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
    Grillon A; Schramm F; Kleinberg M; Jehl F
    PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
    Garrison MW
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
    Drago L; De Vecchi E; Lombardi A; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2002 Dec; 50(6):1059-63. PubMed ID: 12461034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
    Kays MB; Lisek CR; Denys GA
    Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bactericidal index: a new way to assess quinolone bactericidal activity in vitro.
    Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):713-7. PubMed ID: 9222039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.
    Bonfiglio G; Cascone C; Azzarelli C; Cafiso V; Marchetti F; Stefani S
    J Antimicrob Chemother; 2000 Jan; 45(1):115-7. PubMed ID: 10629022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.
    Soussy CJ; Cluzel M; Ploy MC; Kitzis MD; Morel C; Bryskier A; Courvalin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():43-50. PubMed ID: 10404337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of levofloxacin against gram-positive bacteria.
    Montanari MP; Mingoia M; Marchetti F; Varaldo PE
    Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.